JNJ vs RDNT

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

RDNT exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While revenue growth remains positive at 14.8%, the company is struggling with negative profit margins (-0.91%) and a catastrophic collapse in year-over-year EPS growth (-104.5%). There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish reality of insider selling and negative earnings surprises. The valuation is aggressive, with a forward P/E of 58.82 that is not supported by current profitability.